Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Iovance Biotherapeutics, Inc. (IOVA) stock profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing Phase 2 clinical studies, including C-144-01, of its lead product candidate lifileucel for the treatment of metastatic melanoma; C-145-04, of lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145 for recurrent and/or metastatic head and neck squamous cell carcinoma. The company has collaborations and licensing agreements with H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Iovance Biotherapeutics, Inc. was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. The company was incorporated in 2007 and is headquartered in San Carlos, California.

Key facts

SymbolIOVA
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
CEOFrederick G. Vogt
Employees838
HeadquartersSan Carlos, CA, US
IPO2010-10-15
Websitewww.iovance.com

Explore IOVA on Vantafin

  • Iovance Biotherapeutics, Inc. Overview
  • Iovance Biotherapeutics, Inc. Financials
  • Iovance Biotherapeutics, Inc. News
  • Iovance Biotherapeutics, Inc. Events
  • Iovance Biotherapeutics, Inc. SEC filings
  • Iovance Biotherapeutics, Inc. Insider transactions
  • Iovance Biotherapeutics, Inc. Transcripts

Frequently asked questions

What does Iovance Biotherapeutics, Inc. (IOVA) do?
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing Phase 2 clinical studies, including C-144-01, of its lead product candidate lifileucel for the treatment of metastatic melanoma; C-145-04, of lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145 for recurrent and/or metastatic head and neck squamous cell carcinoma. The company has collaborations and licensing agreements with H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Iovance Biotherapeutics, Inc. was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. The company was incorporated in 2007 and is headquartered in San Carlos, California.
Where is IOVA stock listed?
Iovance Biotherapeutics, Inc. trades under the ticker IOVA on NASDAQ.
How can I research IOVA's financials and filings?
Vantafin provides Iovance Biotherapeutics, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the IOVA profile.